BR100 Decreased By (-0.05%)
BR30 Increased By (0.08%)
KSE100 Decreased By (-0.09%)
KSE30 Increased By (0.02%)
AGHA 7.71 Decreased By ▼ -0.21 (-2.65%)
BECO 5.19 Decreased By ▼ -0.01 (-0.19%)
BML 58.00 Decreased By ▼ -1.25 (-2.11%)
BOP 33.45 Decreased By ▼ -0.23 (-0.68%)
CNERGY 10.22 Increased By ▲ 0.41 (4.18%)
CSIL 5.35 Decreased By ▼ -0.07 (-1.29%)
FCCL 54.03 Increased By ▲ 0.51 (0.95%)
FFL 16.38 Decreased By ▼ -0.30 (-1.8%)
FNEL 1.21 No Change ▼ 0.00 (0%)
KEL 7.19 Decreased By ▼ -0.16 (-2.18%)
KOSM 5.57 Decreased By ▼ -0.04 (-0.71%)
LOTCHEM 28.99 Decreased By ▼ -0.12 (-0.41%)
MLCF 95.95 Increased By ▲ 0.45 (0.47%)
NBP 202.61 Decreased By ▼ -1.74 (-0.85%)
NCPL 56.83 Decreased By ▼ -1.41 (-2.42%)
NPL 66.99 Decreased By ▼ -0.80 (-1.18%)
OGDC 318.50 Increased By ▲ 0.56 (0.18%)
PACE 10.66 Decreased By ▼ -0.05 (-0.47%)
PAEL 41.40 Decreased By ▼ -0.43 (-1.03%)
PIBTL 16.56 Increased By ▲ 0.06 (0.36%)
PPL 221.03 Increased By ▲ 1.29 (0.59%)
PRL 47.65 Increased By ▲ 3.06 (6.86%)
PTC 70.61 Decreased By ▼ -0.16 (-0.23%)
SSGC 28.88 Decreased By ▼ -0.05 (-0.17%)
TBL 9.75 Decreased By ▼ -0.09 (-0.91%)
TELE 8.86 Increased By ▲ 0.10 (1.14%)
TPL 17.29 Increased By ▲ 0.84 (5.11%)
TPLP 12.35 Increased By ▲ 0.25 (2.07%)
TREET 22.44 Decreased By ▼ -0.36 (-1.58%)
TRG 59.40 Decreased By ▼ -0.63 (-1.05%)
World

US cancels $590 million contract with Moderna for bird flu shot

Published Updated
Photo: Reuters
Photo: Reuters
By

WASHINGTON: US President Donald Trump’s administration on Wednesday canceled a $590 million contract with Moderna to develop an avian flu vaccine, the US biotech company said.

It marked the latest move against vaccines by Health Secretary Robert F. Kennedy Jr, who has spent decades promoting misinformation about immunization.

The contract, announced on January 17 – three days before Trump took office – was for an mRNA vaccine targeting the H5N1 influenza strain, which has been circulating in birds and cattle.

Experts have warned the virus could jump to humans and spark a pandemic.

American pharmaceutical and biotechnology company Moderna disclosed the news as it announced positive results from an early stage clinical trial of 300 people designed to test safety and immune response.

Moderna beats COVID vaccine sales expectations as deferred revenue rolls in

“While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,” said CEO Stephane Bancel in a statement.

“These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.”

The statement added Moderna would “explore alternatives” for funding the development and manufacturing of the vaccine.

Dr. Ashish Jha, a public health expert who served as former president Joe Biden’s Covid-19 response coordinator, reacted with dismay.

“The attack on mRNA vaccines is beyond absurd,” he posted on X. “It was President Trump’s Operation Warp Speed that gave us mRNA vaccines.”

Comments

Comments are closed for this article.